DLT

Toobit to Showcase Leading Cryptocurrency Exchange as an Exhibitor at TechEx Global in London

Retrieved on: 
Thursday, November 30, 2023

London, UK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Toobit, the innovative cryptocurrency exchange, is thrilled to announce its prominent participation as an exhibitor at TechEx Global, scheduled to be held from November 30th to December 1st, 2023, at Olympia, London.

Key Points: 
  • London, UK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Toobit, the innovative cryptocurrency exchange, is thrilled to announce its prominent participation as an exhibitor at TechEx Global, scheduled to be held from November 30th to December 1st, 2023, at Olympia, London.
  • Attendees are encouraged to visit Toobit's booth at number 146 during this highly anticipated event.
  • TechEx Global is an illustrious platform that brings together leading technology ecosystems against the backdrop of London's iconic cityscape, fostering networking opportunities and collaborative discussions.
  • Celebrating over six years of successful co-located events, TechEx Global has gained prominence for gathering industry experts, visionaries, and pioneers, providing a platform for insightful discussions, sharing real-life use cases, and offering comprehensive insights into current industry trends.

Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Tuesday, November 28, 2023

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced a clinical update regarding its proprietary anti-PSMA antibody drug conjugate (ADC) ARX517 in the ongoing APEX-01 Phase 1 / 2 dose escalation and dose expansion clinical trial in metastatic castration-resistant prostate cancer (mCRPC).

Key Points: 
  • Following the completion of the 21-day DLT observation period from APEX-01 dose escalation Cohort 9 (3.4 mg/kg), no DLTs or SAEs were observed.
  • A PSA decrease was not reported in the third patient because the patient had non-PSA secreting mCRPC.
  • On Monday November 27, the safety monitoring committee (SMC) voted to dose escalate to 4.5 mg/kg (Cohort 10) as well as expand patients at the 3.4 mg/kg dose (Cohort 9).
  • We believe this is a direct result of the stability of conjugation supported by PK data presented at ESMO last month.

Blockchain Laboratories incorporates W3 SaaS in Dubai International Financial Centre (DIFC) to Build Tokenization Platforms for a Better Future

Retrieved on: 
Tuesday, November 28, 2023

Dubai, UAE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Blockchain Laboratories, an innovative Web3 venture studio , is excited to announce the opening of its new wholly owned subsidiary W3 SaaS Technologies Ltd in the prestigious Dubai International Financial Centre (DIFC).

Key Points: 
  • Dubai, UAE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Blockchain Laboratories, an innovative Web3 venture studio , is excited to announce the opening of its new wholly owned subsidiary W3 SaaS Technologies Ltd in the prestigious Dubai International Financial Centre (DIFC).
  • As a pioneer in the industry, Blockchain Laboratories focuses on creating ESG (Environmental, Social, and Governance) digital assets that align investments with sustainability principles.
  • Some of the critical solutions offered by Blockchain Laboratories include:
    Web3 SaaS: Blockchain Laboratories developed a specialized Software as a Service (SaaS) solution that integrates web3 technologies.
  • By getting a commercial license for DLT services in the Dubai International Financial Centre (DIFC) , Blockchain Laboratories’ W3 SaaS aims to strengthen its position as a global leader in the tokenization space.

MicroAlgo Inc. Developed QSDLT to Provide a More Secure Foundation for Bitcoin and Other Cryptocurrency Systems

Retrieved on: 
Wednesday, December 27, 2023

BEIJING, Dec. 27, 2023 /PRNewswire/ -- MicroAlgo Inc. (NASDAQ: MLGO) (the "Company" or "MicroAlgo"), today announced the quantum shield distributed ledger technology (QSDLT), designed to provide a stronger, more secure foundation for Bitcoin and other cryptocurrency systems.

Key Points: 
  • BEIJING, Dec. 27, 2023 /PRNewswire/ -- MicroAlgo Inc. (NASDAQ: MLGO) (the "Company" or "MicroAlgo"), today announced the quantum shield distributed ledger technology (QSDLT), designed to provide a stronger, more secure foundation for Bitcoin and other cryptocurrency systems.
  • To protect the Bitcoin system from the threat of quantum computers, MicroAlgo Inc.'s QSDLT was created as an innovative solution.
  • MicroAlgo Inc.'s QSDLT provides the Bitcoin system with a robust defence against quantum algorithms with its strong anti-quantum algorithmic capabilities, making transactions secure and tamper-proof.
  • As the threat of quantum computing emerges, the emergence of MicroAlgo Inc.'s QSDLT marks the dawn of a new era of Bitcoin security.

CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors

Retrieved on: 
Wednesday, December 20, 2023

The successful completion of the first patient dosing of SY001  demonstrates the advanced technology of the company's R&D platform and the maturity of the CMC platform.

Key Points: 
  • The successful completion of the first patient dosing of SY001  demonstrates the advanced technology of the company's R&D platform and the maturity of the CMC platform.
  • Only 2 grade 3 adverse events occurred; Common grade 1 - 2 adverse events included fever, elevated C-reactive protein, etc.
  • Based on M-CAR, a functionally enhanced second generation CAR-iMAC has been developed to enhance the effectiveness of the therapy for solid tumors.
  • The mechanism of antigen-dependent activation and polarization of the second generation CAR-iMAC and the mechanisms of solid tumor cell killing were also revealed.

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Tuesday, November 14, 2023

“Immatics has had a strong quarter and made steady progress both in terms of the advancement of our clinical programs and in business development.

Key Points: 
  • “Immatics has had a strong quarter and made steady progress both in terms of the advancement of our clinical programs and in business development.
  • An update on the clinical development plan is expected in the first quarter of 2024.
  • An update on the clinical development plan is expected in the first quarter of 2024.
  • On September 11, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

Retrieved on: 
Monday, December 11, 2023

The poster can be viewed on the MEI Pharma website here: https://meipharma.com/ash2023.html .

Key Points: 
  • The poster can be viewed on the MEI Pharma website here: https://meipharma.com/ash2023.html .
  • The second stage of the study is ongoing and is evaluating voruciclib in combination with venetoclax in patients with R/R AML.
  • The primary objectives of the study are to determine the safety and biologic effective dose of voruciclib monotherapy or voruciclib in combination with venetoclax.
  • Secondary objectives of the study include assessing the preliminary efficacy, pharmacokinetics, pharmacodynamics, and biomarkers of voruciclib monotherapy or voruciclib in combination with venetoclax.

OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration

Retrieved on: 
Wednesday, November 29, 2023

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced positive results from a Phase 1 study evaluating the safety and tolerability of OLX10212 for the treatment of Age-Related Macular Degeneration (AMD).

Key Points: 
  • OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced positive results from a Phase 1 study evaluating the safety and tolerability of OLX10212 for the treatment of Age-Related Macular Degeneration (AMD).
  • This phase 1 study is a multi-center, single-dose, dose-escalating study to evaluate the safety and tolerability of OLX10212 in patients with neovascular AMD.
  • The primary endpoints of this study were safety and tolerability assessments associated with each intravitreal OLX10212 injection.
  • The safety and tolerability evaluations, together with preliminary BCVA improvement of OLX10212 encourage further development of OLX10212 for AMD.

Capgemini Collaborates with Euroclear for Successful Launch of Digital Financial Market Infrastructure (D-FMI)

Retrieved on: 
Tuesday, November 21, 2023

Capgemini announced today the recent collaboration with Euroclear to successfully launch its Digital Securities Issuance (D-SI) service, the first key milestone of Euroclear’s Digital Financial Market Infrastructure (D-FMI) strategy.

Key Points: 
  • Capgemini announced today the recent collaboration with Euroclear to successfully launch its Digital Securities Issuance (D-SI) service, the first key milestone of Euroclear’s Digital Financial Market Infrastructure (D-FMI) strategy.
  • Capgemini acted as the lead system integrator on the D-FMI program, providing a comprehensive range of services, including consulting, design, implementation, and testing.
  • Capgemini was also involved in the overall integration and orchestration of the new D-FMI platform within Euroclear’s existing systems and infrastructure.
  • “We are proud to partner with Euroclear to revolutionize the traditional financial market infrastructure through the D-FMI program.

Raiffeisen Schweiz Joins SIX Digital Exchange, Expanding the Digital Financial Landscape in Switzerland

Retrieved on: 
Monday, December 18, 2023

ZURICH and LENZBURG, Switzerland, Dec. 18, 2023 /PRNewswire/ – Raiffeisen Schweiz , a leading Swiss banking group, joins SDX , the world's first fully regulated financial market infrastructure for digital assets.

Key Points: 
  • ZURICH and LENZBURG, Switzerland, Dec. 18, 2023 /PRNewswire/ – Raiffeisen Schweiz , a leading Swiss banking group, joins SDX , the world's first fully regulated financial market infrastructure for digital assets.
  • SDX, licensed by the Swiss Financial Market Supervisory Authority (FINMA), operates a stock exchange and CSD utilizing distributed ledger technology (DLT).
  • These memberships position Raiffeisen Schweiz at the forefront of the digital asset revolution and align with its ambition to issue native digital products upon joining the SDX CSD.
  • "By joining the SDX ecosystem, Raiffeisen Switzerland increases its footprint and experience in digital assets with the aim of actively contributing to the development of the digital assets industry and product landscape", says Werner Leuthard, Head of Trading at Raiffeisen Switzerland.